EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial

Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner, Paula Abreu, Weihang Bao, Wayne Wisemandle, Wajeeha Ansari iD, Magdalena Alicja Harrington, Abraham Simón-Campos, Kara W Chew iD, Rienk Pypstra, James M Rusnak

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae551 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Jennifer Hammond und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Research and Development, Pfizer, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Ritonavir, COVID-19 Drug Treatment, Antiviral Agents, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral treatment for mild to moderate coronavirus disease 2019 (COVID-19).

Methods

This phase 2/3, double-blind, randomized (1:1) study assessed oral NMV/r 300 mg/100 mg versus placebo every 12 hours for 5 days in high-risk, unvaccinated, nonhospitalized, symptomatic adults with COVID-19 from 343 sites across 21 countries. In testing the primary endpoint of COVID-19‒related hospitalization and all-cause deaths and key secondary endpoints, including symptom duration and COVID-19‒related medical visits, type I error was controlled with prespecified sequential testing and the Hochberg procedure.

Results

Among 2113 randomized patients enrolled from July 2021 through December 2021, 1966 (NMV/r, n = 977; placebo, n = 989) were included in the prespecified analysis population (symptom onset ≤5 days, did not receive monoclonal antibodies). NMV/r significantly reduced times to sustained alleviation (median, 13 vs 15 days; hazard ratio = 1.27, P < .0001) and resolution (16 vs 19 days; hazard ratio = 1.20, P = .0022) through day 28 and significantly reduced the number of COVID-19‒related medical visits and the proportion of patients with such visits. Hospitalized patients treated with NMV/r had shorter stays, none required intensive care unit admission or mechanical ventilation, and all were discharged to home/self-care. Fewer NMV/r-treated patients required additional treatment for COVID-19. No NMV/r-treated patients died through week 24 compared with 15 placebo-treated patients.

Conclusions

In addition to reducing COVID-19‒related hospitalization or death from any cause through day 28, NMV/r was found to also reduce duration of COVID-19 symptoms and utilization of healthcare resources versus placebo in patients at high risk of progressing to severe disease. Clinical Trial Information ClinicalTrials.gov, NCT04960202, https://clinicaltrials.gov/study/NCT04960202

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirCOVID-19 Drug TreatmentAntiviral AgentsCOVID-19Patient Acceptance of Health CareHumansMaleFemaleMiddle AgedDouble-Blind MethodAdultAgedHospitalizationSARS-CoV-2Treatment Outcome

Stichwörter der Autor:innen

COVID-19 drug therapyEPIC-HRnirmatrelvirritonavirsymptoms

Substanzen

RitonavirAntiviral Agents

Autor:innen und Institutionen

  • Pfizer Research and Development, Pfizer, Collegeville, Pennsylvania, USA.
  • Pfizer Research and Development, Pfizer, Cambridge, Massachusetts, USA.
  • Pfizer Research and Development, Pfizer, New York, New York, USA.
  • Pfizer Research and Development, Pfizer, Lake Forest, Illinois, USA.
  • Global Access & Value, Pfizer, New York, New York, USA.
  • Köhler and Milstein Research, Anahuac-Mayab University, Mérida, Yucatan, Mexico.

ORCID-Profile: Wajeeha Ansari, Kara W Chew

Förderung

  • Pfizer Inc

Zitieren

APA

Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Ansari, W., Harrington, M. A., Simón-Campos, A., Chew, K. W., Pypstra, R., & Rusnak, J. M. (2025). Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae551

Vancouver

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae551

BibTeX
@article{Hammond2025,
  author = {Hammond, Jennifer and Leister-Tebbe, Heidi and Gardner, Annie and Abreu, Paula and Bao, Weihang and Wisemandle, Wayne and Ansari, Wajeeha and Harrington, Magdalena Alicja and Simón-Campos, Abraham and Chew, Kara W and Pypstra, Rienk and Rusnak, James M},
  title = {Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae551}
}
Kostenlos starten →